ALPHA EMITTER MARKET ANALYSIS

Alpha Emitter Market, by Type of Radionuclide (Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Astatine-211, Bismuth-213 and Others), by Source (Natural Sources (Uranium-238 and Radium-226) Artificially Produced Sources (Plutonium, Americium, Curium and Californium), by Application (Bone Metastases, Prostate Cancer, Neuroendocrine Tumors, Ovarian Cancer and Others), by End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)-

Published In : Jul 2023
Code : CMI5534
Pages :244
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Alpha Emitter Market: Key Developments

In November 2022, IONETIX Corporation, a molecular imaging diagnostics and therapeutics company, announced that the U.S. Nuclear Regulatory Commission (NRC) had issued a Materials License for its new production facility located in Michigan, U.S. This facility will be the first commercial facility in the U.S., dedicated exclusively to the production and supply of alpha-emitting radionuclides, Actinium-225 (Ac-225) and Astatine-211 (At-211), which are both being used to develop new targeted radionuclide therapies to treat various types of cancer.

In November 2022, NorthStar Medical Radioisotopes, a pharmaceutical company and IBA Worldwide, a medical technology company, announced to sign a new agreement. In this agreement, NorthStar Medical Radioisotopes will purchase third Rhodotron TT300 HE electron beam accelerator from IBA Worldwide. This accelerator will be used for the production of no-carrier added actinium-225 (Ac225), an important therapeutic radioisotope that is in limited supply, and no commercial-scale production technology for this accelerator exists.

In January 2022, RadioMedix, a biotechnology company, and Orano Med, a biotechnology company, announced the initiation of the Phase II clinical trial of AlphaMedix with the treatment of the first patient on December 21, 2021. This trial will evaluate the safety and effectiveness of 212Pb-DOTAMTATE (AlphaMedix) in Peptide Receptor Radionuclide Therapy (PRRT) of naive patients with somatostatin receptorexpressing neuroendocrine tumors (NET).

In June 2022, Alpha Tau Medical Ltd., a medical technology company announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational Device Exemption (IDE) application to start its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using Alpha DaRT.